A mouse study is not a human trial. “Promising” is not the same as “proven.” And unknown risk is not the same as low risk. “Doc, what do you think about peptides?” I get asked this question almost every day. BPC-157. TB-500. CJC-1295. Ipamorelin. MOTS-c. New names seem to appear almost as quickly as new social media posts promoting them. Someone hears about a peptide on a podcast. An influencer says it transformed their recovery. A clinic promises better sleep, more muscle, faster healing, or even longer life. And suddenly, an experimental compound starts looking like established medicine. But before we talk about individual peptides, we need to understand one thing: How do we actually know whether a treatment works—and whether it is safe? I Am Not Anti-Peptide Quite the opposite. Peptides have already transformed medicine. Insulin is a peptide hormone. Modern incretin medications have revolutionized the treatment of obesity and diabetes. Other peptide-based drugs are used throughout endocrinology and many other areas of medicine. And some experimental peptides being discussed today may eventually become important therapies. But there is a huge difference between a medication studied in thousands of humans and a compound that produced an interesting result in a mouse. They may both be peptides. They do not have the same level of evidence. How Does an Idea Become Medicine? Medical research usually moves through several stages: Laboratory research → Animal research → Human trials → Regulatory review → Ongoing safety monitoring Each step answers different questions. Laboratory Research Researchers may first study a compound in cells or tissues. This can help show how something might work. But a cell in a laboratory dish is not a person. A molecule entering the human body may affect the immune system, metabolism, hormones, organs, and biological pathways that were never part of the original experiment. So when someone says: “Studies show this works.” My first question is: What kind of studies? Animal Research Animal studies are valuable. They can help researchers understand biological effects, dosing, metabolism, and possible toxicity. But animals and humans are different. Something that dramatically improves healing in a mouse may not work in a human. Something that appears safe during a short animal experiment may create problems when people use it for months or years. So when I see exciting animal research, my response is not: “It doesn't work.” My response is: “Great. Now let's study humans.” That is how science is supposed to work. Then Come Human Trials Even human research exists on different levels. Phase 1 Early studies primarily examine safety, dosing, and how the body processes a drug. Phase 2 Researchers begin asking whether it appears to work. Phase 3 Larger studies provide much stronger information about benefits and risks. This distinction matters. A compound being “studied in humans” does not mean it has been proven effective. Twenty people using something for a few weeks cannot tell us what may happen when thousands of people use it for years. Study size matters. Study duration matters. What researchers actually measured matters. A Better Number Does Not Always Mean a Healthier Person This is another place where hype can get ahead of science. A peptide may change a hormone level, inflammatory marker, growth factor, or body-composition measurement. Interesting? Absolutely. But the more important questions are: Did people actually feel better? Did they heal faster? Did they function better? Did they avoid disease? Did they live longer? And what risks came with the benefit? A biological effect is not automatically a meaningful health outcome. The Most Dangerous Phrase: “There Is No Evidence It Is Dangerous” Be careful. That statement can mean: We studied this extensively and have not found a major safety problem. Or it can mean: Almost nobody has studied this properly, so we have no idea what the risks are. Those are completely different situations. UNKNOWN RISK ≠ LOW RISK Not knowing that something is dangerous is not the same as knowing that it is safe. And What Is Actually in the Vial? This question is often overlooked. Even when a particular molecule is scientifically interesting, the product being sold still matters. Is it actually what the label says? Is the dose accurate? Is it sterile? Is it contaminated? Has it been stored correctly? A scientific study using a carefully manufactured product does not automatically validate every vial carrying the same peptide name. The molecule matters. But so do purity, sterility, dose, and manufacturing quality. Then Came Social Media Social media has helped patients become more informed and engaged. But it has also created a major problem: Social media moves much faster than science. A good clinical trial may take years. A viral video takes seconds. And the algorithm does not ask whether a treatment has been properly studied. It asks whether you clicked. That is why repetition can begin to look like proof. But: Popularity is not a phase of clinical research. Testimonials are not clinical trials. A million views do not equal one well-designed human study. My Position I am excited about the future of peptide medicine. Some of today's experimental compounds may become tomorrow's important therapies. Others will fail. Some may reveal risks we do not yet understand. That is normal. That is science. What concerns me is when we skip the process—when animal data becomes a treatment claim, a theoretical mechanism becomes a guarantee, and patients effectively become the experiment. Innovation is important. But we should never have to abandon scientific standards to pursue it. Before Trying Any New Peptide, Ask Five Questions Has it actually been studied in humans? How many humans? What benefit was actually proven? How long were people followed? Where did the product actually come from? Those five questions can eliminate a remarkable amount of medical misinformation. The Bottom Line I believe peptide medicine has an exciting future. But the future of medicine should be built on evidence—not algorithms. We should be open to innovation while remaining honest about what we know, what we do not know, and what may still carry unknown risk. Sometimes the most responsible answer a physician can give is: “We don't know yet.” That may not go viral. But it may keep patients safe. Next: Part 2—What Exactly Is a Peptide? Next, we will look at what peptides actually are, how they work in the body, why some have become extraordinary medications—and what separates established peptide medicine from the rapidly expanding world of experimental peptide therapy. Then we will begin examining the peptides everyone is asking about, one by one. Evidence over hype. Science over social media. Patient safety first. — Alex Foxman, MD, FACP, ABOM Double Board-Certified in Internal Medicine & Obesity Medicine Beverly Hills Institute This article is for general educational purposes and does not constitute individualized medical advice.

“Doc, what do you think about peptides?” I get asked this question almost every day. BPC-157. TB-500. CJC-1295. Ipamorelin. MOTS-c. Semax. Selank. GLP-1s. The list keeps growing—and social media is moving much faster than the science. Some peptides have transformed modern medicine. Others are being injected into people with surprisingly little meaningful human data. Those are not the same thing. Over the next several weeks, I’m launching a 5-part series on peptides on BHInstitute.com that will take a hard, scientific look at what we actually know. We’ll start with something that social media almost never explains: How does medical research actually work? • What does a mouse study really tell us?• What is the difference between a Phase 1 trial and a Phase 3 trial?• What does FDA approval actually mean? And perhaps most importantly: When someone says, “There is no evidence that this peptide is dangerous,” does that actually mean it is safe? The answer may surprise you. Then we’ll go peptide by peptide—separating established medicine from legitimate emerging science, experimental therapies, internet hype, and products that may simply be getting dangerously ahead of the evidence. My position is simple: I am not anti-peptide. I am anti-bad science. Some of these compounds may ultimately become important therapies. But your body is not a laboratory. A million views do not equal one well-designed human clinical trial. And “promising” should never be confused with “proven.” As physicians, our responsibility is not to chase every trend. It is to understand the science, evaluate the evidence, protect our patients, and still remain open to where medicine is going next. The future of peptide medicine may be incredibly exciting. But we should never have to sacrifice patient safety just to get there first. Coming soon: PART 1: Before You Inject the Hype—How Medical Research Actually Works Follow along here and on BHInstitute.com. Alex Foxman, MD, FACP, ABOM Double Board-Certified in Internal Medicine & Obesity Medicine

As we head into the Fourth of July weekend, we want to wish you a safe, healthy, and joyful holiday. Please remember that our team is available 24/7 for your medical needs. If a health concern comes up over the holiday weekend, call us first before going to urgent care, the emergency room, or the hospital — unless it is a true life-threatening emergency. Many issues can be handled quickly by phone, telehealth, or, when appropriate, an in-home visit. Calling us first may help you avoid unnecessary urgent care visits, long ER waits, hospital exposure, and added stress. When to Call Us First Please reach out for concerns such as: Fever, cough, sore throat, urinary symptoms, or possible infection Medication questions, side effects, missed doses, or refill concerns Mild to moderate injuries, cuts, sprains, or falls Dehydration, nausea, vomiting, diarrhea, or stomach pain Blood pressure, blood sugar, or heart rate concerns New or worsening symptoms that worry you For chest pain, severe shortness of breath, stroke symptoms, severe allergic reactions, major trauma, or loss of consciousness, please call 911 immediately. Quick Health Tips for the Holiday Weekend Stay hydrated. Heat, alcohol, salty foods, and time outdoors can quickly lead to dehydration. Be mindful with alcohol. Alcohol can interact with medications, worsen dehydration, increase fall risk, and raise blood pressure. Protect yourself from the sun. Use sunscreen, wear a hat, seek shade, and avoid prolonged heat exposure. Watch for heat illness. Dizziness, weakness, headache, nausea, confusion, or feeling faint can be warning signs. Be careful around fireworks and grills. Keep children away from fireworks and use caution around flames, propane, and hot surfaces. Do not ignore symptoms. Urinary symptoms, respiratory symptoms, wounds, infections, or worsening pain should be addressed early. Keep medications on schedule. Make sure you have enough medication before traveling or leaving for the weekend. Call Before You Go Urgent care, ER, and hospital visits are sometimes necessary — but not always. Our goal is to help you get the right level of care at the right time. This Fourth of July weekend, please remember: We are here for you 24/7. Call us first with any medical needs. Wishing you and your family a happy, safe, and healthy Fourth of July weekend.

Artificial intelligence is quickly becoming one of the most talked-about topics in health care. Patients are hearing that AI can review scans, interpret lab results, predict disease risk, summarize medical records, and even suggest possible diagnoses. At Beverly Hills Institute, we believe this is an exciting moment in medicine — but also one that requires clarity. AI can be a powerful medical tool. It can help physicians organize information, recognize patterns, improve efficiency, and support more personalized care. In the right setting, AI may help identify risks earlier and allow doctors to make better-informed decisions. But AI is not a physician. It does not perform a physical exam. It does not know your full medical history unless the information entered is complete and accurate. It does not understand your personal goals, family history, lifestyle, medications, risks, or subtle changes in how you feel. It cannot independently diagnose, order testing, prescribe medication, or take responsibility for your care. That distinction matters. Patients are increasingly using online AI tools to interpret symptoms, lab results, imaging reports, and medication questions. While these tools may provide general education, they can also miss important warning signs, misunderstand context, or provide information that sounds confident but may not apply to the individual patient. At Beverly Hills Institute, our approach is different. We combine modern medical technology with physician-led care. As a concierge internal medicine and preventive care practice, we focus on understanding the whole patient — not just a lab number, scan result, or algorithm-generated answer. Our goal is to help patients make informed decisions based on their personal risk factors, medical history, lifestyle, family history, and long-term health goals. This is especially important in preventive and longevity medicine. The future of medicine is moving toward earlier detection, better risk prediction, more personalized testing, and proactive health planning. AI will likely play an important role in that future. But technology should support the physician-patient relationship, not replace it. A computer can process data.A physician applies judgment. A computer can identify a pattern.A physician understands the patient behind the pattern. A computer can provide information.A physician helps determine what that information means for you. The best medical care happens when advanced technology is combined with clinical experience, careful interpretation, and a trusted physician who knows the patient personally. AI is changing medicine — and that is a good thing. But your health decisions should still be guided by a licensed medical professional who understands you, your risks, and your goals. At Beverly Hills Institute, we use innovation to enhance care, not replace the human connection that great medicine requires. Bottom Line AI is a powerful tool, but it is not your doctor. The future of medicine will be smarter, faster, and more personalized — but it still requires physician guidance, medical judgment, and a relationship built on trust.

Cancer care is undergoing a major shift. For decades, medicine has focused on finding cancer after symptoms appear or after a cancer has already advanced. Today, two major areas of research are pushing us toward a more proactive model: detecting cancer earlier and reducing the metabolic conditions that may increase cancer risk or progression. At the 2026 American Society of Clinical Oncology Annual Meeting, two topics stood out: new data on the GRAIL Galleri® multi-cancer early detection blood test and emerging research on GLP-1 medications, including semaglutide and tirzepatide, and their possible relationship to cancer outcomes. At Beverly Hills Institute, we believe the future of preventive medicine is not simply treating disease after it appears. It is identifying risk earlier, acting sooner, and helping patients live longer, healthier lives. The GRAIL Galleri Test: A Blood Test Designed to Look for More Than 50 Cancers The Galleri test is a blood test designed to detect cancer signals from DNA shed into the bloodstream by cancer cells. It is not a genetic risk test. It does not tell you whether you may develop cancer in the future. Instead, it looks for signals that may suggest cancer is already present and may help predict where in the body that cancer signal is coming from. This matters because many dangerous cancers do not currently have routine screening tests. We routinely screen for breast cancer, colon cancer, cervical cancer, prostate cancer in selected patients, and lung cancer in high-risk smokers. But many cancers, including pancreatic, ovarian, liver, esophageal, and other aggressive cancers, are often found late because there has not been a practical screening tool for the general population. Galleri is intended to be used in addition to, not instead of, standard recommended cancer screenings such as mammography, colonoscopy, PSA testing when appropriate, cervical cancer screening, and lung cancer screening for eligible patients. What Was Presented at ASCO 2026? At ASCO 2026, GRAIL presented encouraging new data from two major studies: the NHS-Galleri trial and the PATHFINDER 2 study. Together, these studies suggest that the Galleri multi-cancer early detection blood test may help find more cancers earlier, including cancers that do not currently have routine screening options. The NHS-Galleri trial included more than 142,000 adults ages 50 to 77 in England. While the study did not meet its primary endpoint of reducing the combined number of stage III and stage IV cancers, the results showed important benefits over repeated annual testing. Among 12 prespecified deadly cancers, Galleri reduced stage IV cancer diagnoses by 9% in the first screening round, 22% in the second round, and 26% in the third round, with an overall 14% reduction after three rounds. The study also showed a 16% increase in stage I and II cancer diagnoses, a four-fold increase in screen-detected cancers, and a 25% reduction in cancers diagnosed after emergency presentation. These findings suggest Galleri may help shift cancer detection earlier, when patients may have more treatment options and better outcomes. The PATHFINDER 2 study included 35,878 adults age 50 and older in the United States and Canada. When Galleri was added to standard recommended screening, cancer detection by screening increased 6.5-fold. More than half of the new cancers detected by Galleri, 53.0%, were stage I or II, and 70.9% were detected at stages I to III. Importantly, 71.3% of the new cancers detected had no USPSTF A or B recommended screening option. Galleri also showed strong test performance in PATHFINDER 2, with a positive predictive value of 60.3%, specificity of 99.6%, a false-positive rate below 0.4%, and cancer signal origin accuracy of 91.3%. The key message is that Galleri does not replace standard cancer screening, but the 2026 ASCO data supports its role as an additional tool that may help detect more cancers earlier, reduce stage IV diagnoses over time, and identify cancers that are often missed until they are advanced. What Does This Mean for Patients? The most important message is this: early detection matters. Cancer outcomes are often dramatically different when cancer is found before it spreads. A stage I or II cancer may be treatable with curative intent. A stage IV cancer is often much harder to treat and may require systemic therapy, complex treatment decisions, and long-term disease management. The Galleri test is not perfect. A negative result does not rule out cancer. A positive result requires appropriate follow-up testing, such as imaging or other diagnostic evaluation. False positives and false negatives can occur. The test has also not been cleared or approved by the FDA, although it is performed in a CLIA-certified, CAP-accredited laboratory. But the new ASCO data adds to a growing body of evidence that multi-cancer early detection may become an important part of a modern preventive medicine strategy. Beverly Hills Institute Recommendation At Beverly Hills Institute, we recommend the GRAIL Galleri multi-cancer early detection blood test annually for patients over age 50. We also recommend considering annual Galleri testing for patients under age 50 who have a personal history of cancer or a significant family history of cancer. This recommendation does not replace standard screening. Patients should still complete appropriate routine screening, including colonoscopy or stool-based colon cancer screening, mammography, cervical cancer screening, prostate cancer screening when appropriate, dermatologic skin checks, and lung cancer screening for eligible patients. Our approach is additive: use the best standard tools available, and when appropriate, add newer technologies that may help detect cancers that routine screening may miss. GLP-1 Medications and Cancer: Another Important ASCO 2026 Topic Another major topic at ASCO 2026 was the relationship between GLP-1 receptor agonist medications and cancer progression. These medications include drugs such as semaglutide and tirzepatide, which are widely used for type 2 diabetes, obesity, and medical weight management. A real-world analysis presented at ASCO evaluated 12,112 patients with stage I to III cancer and compared patients who received GLP-1 medications with patients who received DPP-4 inhibitors. The cancers studied included breast cancer, prostate cancer, non-small cell lung cancer, colorectal cancer, liver cancer, kidney cancer, and pancreatic cancer. The study found that GLP-1 use was associated with reduced progression to stage IV disease in several obesity-related cancers. Statistically significant reductions were seen in non-small cell lung cancer, breast cancer, colorectal cancer, and hepatocellular carcinoma. For example, progression to stage IV disease occurred in 10% of GLP-1 users versus 22% of DPP-4 inhibitor users in non-small cell lung cancer, 10% versus 20% in breast cancer, 13% versus 22% in colorectal cancer, and 19% versus 28% in hepatocellular carcinoma. The study also found that higher tumor GLP-1 receptor expression was associated with a 33% lower risk of death across the tumor types studied, and a 45% lower risk of death in breast cancer. This does not prove that GLP-1 medications prevent cancer progression. The study was observational, meaning it can show an association but cannot prove cause and effect. Researchers appropriately noted that randomized controlled trials are needed. Still, the findings are fascinating and consistent with a broader medical reality: obesity, insulin resistance, inflammation, and metabolic disease are deeply connected to cancer risk and overall health. The Bigger Picture: Prevention, Metabolism, and Early Detection The future of medicine will likely combine several strategies: Earlier cancer detection Better use of imaging and blood-based screening Personalized risk assessment Metabolic optimization Weight management Exercise and muscle preservation Reduction of inflammation and insulin resistance More aggressive prevention before disease becomes advanced At Beverly Hills Institute, this is exactly how we think about preventive care. The annual wellness visit is no longer just a basic physical. It is an opportunity to review cancer risk, cardiovascular risk, metabolic health, body composition, family history, medications, lifestyle, and advanced screening options. The goal is not simply to live longer. The goal is to live better, with more years of strength, independence, and quality of life. Final Thoughts The ASCO 2026 data does not mean we have solved cancer screening. It does not mean one blood test can replace colonoscopy, mammography, PSA testing, cervical cancer screening, or other proven tools. But it does show that cancer screening is evolving. The GRAIL Galleri test may help identify cancers that do not currently have routine screening options. GLP-1 medications may have broader effects on metabolic and cancer-related outcomes than previously understood. Together, these developments reinforce a central idea: prevention and early detection are becoming more powerful. At Beverly Hills Institute, we believe patients should have access to thoughtful, advanced, evidence-informed preventive care. For many patients, especially those over 50 or those with a personal or family history of cancer, annual GRAIL Galleri testing should be part of that conversation.e part of that conversation.

Why Advanced Heart Risk Testing May Be One of the Most Important Preventive Health Conversations This Year For decades, patients have been told to “check your cholesterol.” Most people know their LDL cholesterol, often called “bad cholesterol,” and HDL cholesterol, often called “good cholesterol.” But the newest cholesterol guidance from the American College of Cardiology and American Heart Association makes something very clear: traditional cholesterol testing is important, but it may not tell the whole story. The updated 2026 cholesterol guideline emphasizes a more personalized approach to cardiovascular prevention, including earlier treatment, clearer LDL cholesterol goals, and selective use of additional tests such as coronary artery calcium scoring, Lipoprotein(a), and Apolipoprotein B. These tools can help identify hidden cardiovascular risk before a heart attack or stroke occurs. At Beverly Hills Institute, this is exactly the kind of prevention we discuss during an Annual Wellness Visit: not just whether your cholesterol is “normal,” but whether your overall cardiovascular risk is truly being understood. Why “Normal Cholesterol” Can Be Misleading A standard lipid panel usually includes total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides. These numbers are very useful, but they do not always fully capture a patient’s true risk. Two people can have the same LDL cholesterol level but very different risk profiles. One may have no plaque in the arteries, while the other may already have early coronary artery disease. One may have a strong family history of heart attack. Another may have diabetes, elevated inflammatory risk, high triglycerides, or a genetically elevated Lipoprotein(a). That is why modern preventive medicine is moving beyond simply asking, “Is your cholesterol high?” and instead asking, “What is your actual risk of developing plaque, heart attack, or stroke?” LDL Goals Are Back One of the most important updates in the 2026 guideline is the return of LDL cholesterol treatment goals. For prevention of a first heart attack or stroke, the guideline identifies LDL-C goals based on risk level. For many patients at borderline or intermediate risk, the LDL-C goal is less than 100 mg/dL. For high-risk patients, the goal is less than 70 mg/dL. For patients with known cardiovascular disease who are at very high risk, the goal may be less than 55 mg/dL. This matters because cardiovascular disease is not something that suddenly appears at age 65. Plaque builds over years and decades. The earlier we identify risk, the more opportunity we have to intervene with lifestyle, nutrition, exercise, weight management, blood pressure control, diabetes prevention, and when appropriate, medication. Coronary Artery Calcium Scan: Seeing Plaque Before Symptoms A coronary artery calcium scan, often called a CAC scan, is a low-radiation CT scan that looks for calcified plaque in the coronary arteries. It does not require contrast dye, and it can help determine whether a patient already has early evidence of coronary artery disease. The new guideline supports selective use of CAC scoring in men age 40 and older and women age 45 and older who have borderline or intermediate 10-year cardiovascular risk when the result would help guide a decision about statin therapy. Any amount of coronary artery calcium supports a more serious discussion about LDL lowering, with lower LDL goals recommended as the calcium score increases. In practical terms, this test can be very helpful for patients who say: “My cholesterol is borderline, but I don’t want to take medication unless I really need it.” Or: “My cholesterol does not look that bad, but heart disease runs in my family.” A CAC scan can help move the conversation from guesswork to evidence. Lipoprotein(a): The Genetic Risk Many Patients Have Never Checked Lipoprotein(a), or Lp(a), is a cholesterol-related particle that is largely genetically determined. Unlike LDL cholesterol, it is not significantly changed by diet, exercise, or weight loss. That does not mean lifestyle is unimportant. It means that if Lp(a) is high, we need to know about it so we can manage the rest of the patient’s risk more aggressively. The 2026 guideline states that Lp(a) should be measured at least once in adulthood. A high Lp(a), defined as 125 nmol/L or greater or 50 mg/dL or greater, is associated with increased long-term risk of heart attack and stroke. Very high levels are associated with even greater risk. This is especially important for patients with: A family history of early heart diseaseA personal history of unexplained cardiovascular diseaseHigh cholesterol despite a healthy lifestyleAortic valve diseaseA heart attack or stroke at a younger age Many patients with elevated Lp(a) have no idea they carry this risk because it is not included in a routine cholesterol panel. Apolipoprotein B: Counting the Dangerous Particles Apolipoprotein B, or ApoB, is another advanced marker that can help refine cardiovascular risk. ApoB reflects the number of atherogenic particles in the blood, meaning the particles that can enter the artery wall and contribute to plaque formation. In some patients, LDL cholesterol can look acceptable while ApoB remains elevated. This is more common in people with insulin resistance, metabolic syndrome, diabetes, high triglycerides, obesity, or cardiovascular-kidney-metabolic risk. The guideline notes that ApoB may be useful to assess residual cardiovascular risk and guide treatment in certain patients, particularly those with type 2 diabetes, high triglycerides, cardiovascular-kidney-metabolic syndrome, or known cardiovascular disease. In other words, ApoB may help answer a more precise question: how many plaque-forming particles are actually circulating in the bloodstream? Prevention Is No Longer One-Size-Fits-All The most important message from the new cholesterol guidance is that prevention should be personalized. For some patients, a standard lipid panel and healthy lifestyle counseling may be enough. For others, especially those with family history, metabolic risk, diabetes, elevated triglycerides, obesity, inflammatory conditions, or unclear risk, additional testing can provide a much clearer picture. This does not mean every patient needs every test. It means the right patient should get the right test at the right time. What We Discuss During an Annual Wellness Visit At Beverly Hills Institute, preventive care is not just about checking boxes. During an Annual Wellness Visit, we review cardiovascular risk in a more complete way, including: Blood pressureCholesterol and triglycerides Blood sugar and insulin resistance risk Weight, waist circumference, and body compositionFamily historySmoking history Sleep, stress, nutrition, and exercise Medication options when appropriate Advanced testing such as CAC score, Lp(a), and ApoB when clinically useful The goal is not simply to treat a number. The goal is to prevent the heart attack, stroke, hospitalization, disability, or loss of quality of life that may occur years later if risk is missed. The Bottom Line Your cholesterol panel is important, but it may not be enough. The newest cholesterol guideline reinforces what preventive physicians have been seeing for years: cardiovascular risk is more complex than a single LDL number. Coronary artery calcium scoring, Lipoprotein(a), and Apolipoprotein B can help uncover hidden risk and guide a more personalized prevention plan. If you have a family history of heart disease, borderline cholesterol, diabetes, high triglycerides, elevated blood pressure, weight concerns, or simply want a deeper understanding of your long-term health, this is a conversation worth having. At Beverly Hills Institute, our goal is to help patients live longer, healthier, and better lives by identifying risk early and creating a prevention plan that is personalized, proactive, and based on the latest science.

There is growing excitement around human longevity—and for good reason. The intersection of artificial intelligence, advanced medical science, and preventive medicine is beginning to reshape how we think about aging. While headlines often suggest dramatic extensions in lifespan, the more realistic and important shift over the next 5–10 years is an increase in healthspan —the number of years we live strong, independent, and disease-free. The future is not just about living longer. It is about living better for longer. The question is not whether longevity science will advance. It already is. The real question is: Will your body be prepared to take advantage of it? The Three Forces Driving the Longevity Revolution The rapid evolution of longevity is being driven by three major forces working together. 1. Artificial Intelligence and Data AI is transforming medicine by identifying patterns earlier than ever before. It is helping physicians detect disease sooner, personalize treatments, and optimize outcomes using massive datasets that were previously impossible to analyze. From predictive analytics to real-time health monitoring, AI is moving medicine from reactive to proactive. 2. Advances in Medical Science We are seeing breakthroughs in areas such as early cancer detection, cardiovascular risk stratification, metabolic health, and neurodegenerative disease. New tools—including multicancer detection testing, advanced lipid markers like Lipoprotein(a) and Apolipoprotein B, and imaging such as coronary calcium CT scans—are allowing us to identify risk years before symptoms appear. Medicine is no longer just about treating disease. It is about preventing it. 3. A Shift Toward Preventive and Longevity Medicine There is a growing recognition that lifestyle is not just important—it is foundational. The most advanced therapies in the world will not overcome poor sleep, loss of muscle mass, metabolic dysfunction, and chronic inflammation. Longevity starts with biology, and biology is shaped daily by behavior. What Actually Moves the Needle on Longevity Despite all the excitement around future breakthroughs, the most powerful longevity tools already exist today. These are not theoretical. They are proven. 1. Muscle Mass and Strength Muscle is one of the strongest predictors of longevity. It is critical for metabolic health, insulin sensitivity, balance, injury prevention, and survival during illness. Loss of muscle—especially with aging or unmonitored weight loss—directly correlates with increased mortality. This is why resistance training is essential. Not optional. Essential. If your goal is to live longer and better, building and preserving muscle must be a priority. 2. Exercise Beyond Cardio Cardiovascular exercise improves heart health, but longevity requires more than just steps or calories burned. A complete program includes: • Resistance training to build muscle • Cardiovascular training for heart health • Mobility and balance work for injury prevention This combination creates resilience—the ability to withstand stress, illness, and aging. 3. Nutrition: The Mediterranean Foundation The Mediterranean diet remains one of the most evidence-based approaches to longevity. It emphasizes: • Fruits and vegetables • Whole grains and legumes • Healthy fats, especially olive oil • Lean proteins, particularly fish • Minimal processed foods and sugars This pattern has consistently been associated with lower cardiovascular risk, improved metabolic health, and reduced mortality. There is no shortcut here. Nutrition is a long-term investment in your biology. 4. Sleep as a Longevity Pillar Sleep is often overlooked, yet it is one of the most powerful drivers of health. Poor sleep impacts: • Hormonal balance • Weight regulation • Cognitive function • Cardiovascular risk Optimizing sleep is not optional in a longevity strategy—it is foundational. The Reality: The Future Rewards the Prepared There is a lot of discussion about people living to 100 or beyond, and while that may become more common, it will not happen by chance. The individuals most likely to benefit from advances in AI, medicine, and longevity science will be those who: • Maintain muscle mass • Optimize metabolic health • Stay physically active • Follow a sustainable, high-quality diet • Prioritize sleep and recovery In other words, those who are biologically prepared. What We Do at Beverly Hills Institute At Beverly Hills Institute, longevity and preventive care are central to everything we do. During the Annual Wellness Visit, we go beyond traditional medicine and focus on both current and emerging tools to improve lifespan and quality of life. This includes: • Advanced cardiovascular risk assessment (including coronary calcium CT, Lipoprotein(a), Apolipoprotein B) • Comprehensive metabolic and body composition analysis• Personalized exercise and nutrition strategies • Preventive and early detection screening, including multicancer detection testing such as the Galleri test • Ongoing monitoring and optimization of health markers Our goal is simple: Help patients live longer, stronger, and healthier lives. Final Thought The future of longevity is not a single breakthrough. It is the combination of technology, science, and daily habits working together. AI may help us detect disease earlier. Medicine may help us treat it more effectively. But lifestyle determines whether we are in a position to benefit at all. If you are 50 today, the goal is not just to live longer. It is to ensure that at 80, 90, 100 and beyond—you are still strong, capable, and thriving. The longevity revolution is already here. The question is: Are you ready for it?

Preventive medicine is one of the most powerful tools we have to extend life and improve quality of life. But there’s a growing problem: more testing is not always better . In fact, over-screening can lead to unnecessary anxiety, invasive procedures, and even harm—without improving outcomes. As a physician focused on prevention and longevity, I see this confusion every day. Patients are increasingly asking about full-body MRIs, advanced biomarker panels, and executive checkups. The key question is simple: Which tests actually help you live longer—and which ones just create noise? Let’s break it down using real science. The Goal of Preventive Screening The purpose of screening is not to find “anything abnormal. ”It is to identify disease early when intervention improves outcomes . For a screening test to be valuable, it must: Detect disease at an earlier, treatable stage Reduce mortality (not just find more disease) Have an acceptable risk-to-benefit ratio Many tests fail this standard. Where Screening Clearly Saves Lives (Evidence-Based) 1. Colon Cancer Screening Colonoscopy remains one of the most effective screening tools in medicine. Reduces colorectal cancer mortality by ~60–70% Allows removal of precancerous polyps before cancer develops Recommended starting at age 45 (earlier if high risk) This is true prevention , not just detection. 2. Cardiovascular Risk Assessment (Modern Approach) Heart disease remains the #1 cause of death—but our tools for risk prediction have evolved significantly. High-Value Tests Coronary Artery Calcium (CAC) Score – CT Scan Directly measures calcified plaque in coronary arteries Strong predictor of future cardiac events A CAC score of 0 = very low short-term risk Higher scores correlate with stepwise increases in risk Supported by large cohort studies (e.g., MESA), CAC scoring often outperforms traditional risk calculators  in guiding statin therapy and prevention strategies. Apolipoprotein B (ApoB) Measures total number of atherogenic particles (LDL, VLDL, remnants) More accurate than LDL-C alone in predicting cardiovascular risk Strongly associated with plaque formation and progression Lipoprotein(a) – Lp(a) Genetically determined risk factor Elevated levels significantly increase risk of: Premature coronary artery disease Stroke Should be checked at least once in a lifetime Why This Matters Traditional lipid panels alone can miss risk.These advanced markers provide a more precise and individualized assessment , allowing earlier and more targeted intervention. 3. Targeted Cancer Screening Certain screenings have strong outcome data: Mammography → reduces breast cancer mortality Low-dose CT (for smokers) → reduces lung cancer mortality Cervical cancer screening → dramatically reduces incidence and death These are supported by large randomized trials and population data. Emerging: Multi-Cancer Early Detection (MCED) Blood-based cancer screening tests (e.g., Galleri)  are gaining attention. What they do: Detect circulating tumor DNA (ctDNA) signals Screen for multiple cancers simultaneously  (including some without standard screening tests) What the science shows so far: Can detect cancers at earlier stages in some cases Specificity is relatively high (low false positive rate) Sensitivity varies by cancer type and stage Important limitations: Best used as a complement , not a replacement, for standard screening Bottom line:  Promising and still evolving. Where Screening Becomes Problematic Full-Body MRI: High Hype, Limited Evidence Full-body MRI is increasingly marketed as a “longevity scan.” Reality: Up to 30–40% of scans show incidental findings Most are benign and clinically irrelevant Triggers cascades of follow-up tests There is no evidence  that full-body MRI improves survival in asymptomatic individuals. Instead, it often leads to: Anxiety Unnecessary procedures Increased cost without benefit Overuse of Broad Biomarker Panels Large, non-targeted lab panels often: Lack clinical validation Produce false positives Lead to overtreatment The goal is not more data—it’s actionable data . The Hidden Risk: Overdiagnosis Overdiagnosis occurs when: A condition is detected that would never cause harm The patient undergoes treatment anyway Common examples: Certain prostate cancers Thyroid nodules Incidental imaging findings Research in JAMA  and BMJ  highlights that overdiagnosis can lead to: Unnecessary surgeries Medication complications Psychological burden What Actually Moves the Needle in Longevity The biggest drivers of lifespan are not exotic tests—they are risk reduction and body composition . 1. Metabolic Health Insulin resistance is a central driver of aging Managing weight, glucose, and inflammation significantly reduces disease risk 2. Body Composition (Not Just Weight) Full Body DEXA scans provide: Fat vs muscle differentiation Visceral fat measurement (strong mortality predictor) Objective tracking over time This is far more actionable than a standard scale. 3. Functional Metrics Sleep quality Physical activity Muscle strength These often outperform lab markers in predicting long-term outcomes. A Smarter Approach to Preventive Medicine Instead of asking, “What tests can I do?”Ask, “What will actually change my outcome?” A high-value preventive strategy includes: Evidence-based screening (age + risk specific) Advanced cardiovascular risk markers (CAC, ApoB, Lp(a)) Selective use of emerging tools (e.g., MCED testing) Body composition and metabolic tracking Continuous monitoring—not one-time testing How We Approach This at Beverly Hills Institute At Beverly Hills Institute, preventive care is not a checklist—it is a personalized, physician-driven strategy . During your Annual Wellness Visit , we: Review all evidence-based screening recommendations  based on your age and risk factors Discuss advanced and emerging tools  such as CAC scoring, ApoB, Lp(a), and multi-cancer detection testing Evaluate what is appropriate—and what is not necessary Focus on interventions that improve both longevity and quality of life , not just generate more data Our goal is simple: Provide clarity in a world of medical noise and guide you toward what truly matters. The Bottom Line Preventive medicine is not about doing more—it’s about doing what works. Some tests (CAC, ApoB, colonoscopy) clearly improve outcomes Others (full-body MRI, indiscriminate panels) often do not Emerging tools like multi-cancer detection are promising—but not yet definitive The future of longevity is built on: Precision. Evidence. Consistency. If you’re considering advanced screening or want a personalized longevity plan, the most important step is working with a physician who understands which tests matter—and why.

In recent years, full-body MRI scans  have exploded in popularity. Companies like Prenuvo market these scans as a revolutionary way to detect cancer, aneurysms, and other diseases before symptoms appear. For many health-conscious individuals, the concept is appealing: spend a few thousand dollars, lie in a scanner for an hour, and supposedly get peace of mind about your entire body. But in reality, the science tells a very different story. Full-body MRI screening for healthy individuals is not recommended by most medical organizations , and the scans frequently lead to false positives, unnecessary testing, and anxiety  without improving health outcomes. Let’s examine why. The Problem With Full-Body MRI Screening 1. High False-Positive Rates One of the biggest issues with whole-body imaging is the detection of incidental findings —abnormalities that appear suspicious but are ultimately harmless. Studies evaluating whole-body MRI screening show: Up to 30–40% of people  have incidental findings on full-body imaging. Approximately 10–15% require additional testing  after the scan. The vast majority of these findings turn out to be benign. A systematic review published in the journal European Radiology  evaluated whole-body MRI screening in asymptomatic individuals and found: Incidental findings occurred in up to 37% of participants Clinically significant findings were rare In other words, many people walk away with an abnormal result that triggers more scans, biopsies, or procedures—without discovering anything dangerous. 2. Detection of “Pseudodisease” Another major problem is the detection of abnormalities that would never cause symptoms during a person’s lifetime . This phenomenon is known as overdiagnosis . Modern imaging is incredibly sensitive and can detect very small abnormalities that may never progress or cause harm. Once identified, however, these findings often lead to: Additional imaging Invasive biopsies Surgery Psychological stress The result is treatment of conditions that never needed treatment in the first place . 3. Lack of Evidence That It Improves Survival Perhaps the most important point: there is no evidence that whole-body MRI screening improves life expectancy or reduces mortality in healthy individuals. Screening tests are only valuable when they meet certain criteria: They detect disease early Early detection changes outcomes The benefits outweigh the harms Full-body MRI screening has not met these standards  in large population studies. This is why organizations such as the American College of Radiology caution against routine whole-body screening in asymptomatic individuals. The Psychological Cost of “Too Much Information” Another overlooked issue is the psychological impact of uncertain findings . Patients frequently experience: Anxiety Stress while waiting for follow-up tests Fear about possible cancer or serious disease Even when additional tests ultimately show nothing concerning, the process can take weeks or months. Ironically, a test marketed as providing peace of mind can often produce the opposite. The Financial Cost Full-body MRI scans typically cost $2,500–$4,000  and are not covered by insurance. But the true cost is often higher. When incidental findings occur, patients may require: Additional MRI or CT scans Specialist consultations Biopsies Follow-up imaging These downstream costs can quickly exceed the price of the initial scan. What Actually Works in Preventive Medicine While full-body MRI screening lacks evidence, many preventive strategies are proven to improve health and longevity . Evidence-based preventive care includes: Cancer Screening Recommended screenings include: Colon cancer screening starting at age 45 Mammography for breast cancer Cervical cancer screening Lung cancer screening for high-risk individuals Multicancer Detection screening at age 50 These tests are supported by REAL research showing reduced mortality. Cardiovascular Risk Assessment Heart disease remains the leading cause of death. Effective prevention includes: Cholesterol testing Blood pressure monitoring Diabetes screening Coronary artery calcium scoring for selected patients These tools help identify risk early and guide treatment before major events occur. Metabolic and Lifestyle Optimization The strongest predictors of long-term health include: Maintaining healthy body composition Regular physical activity Adequate protein intake Sleep optimization Blood sugar control Evidence-based weight management programs—especially those integrating modern therapies like GLP-1 and GIP medications—can dramatically reduce risks of diabetes, heart disease, and metabolic syndrome. The Role of Personalized Preventive Medicine The most effective preventive care does not rely on a single test. Instead, it combines: Comprehensive medical evaluation Evidence-based screening Risk assessment Lifestyle intervention Ongoing monitoring This approach identifies real risk factors and addresses them before disease develops . The Bottom Line Full-body MRI scans may sound appealing, but for most healthy individuals they offer more risk than benefit . The evidence shows: High rates of false positives Frequent incidental findings Lack of proven mortality benefit Significant financial and psychological costs True preventive medicine focuses on proven screening, metabolic health, and personalized medical care —not expensive tests that create unnecessary worry. Before pursuing advanced imaging marketed as “peace of mind,” it’s worth asking a simple question: Is this test supported by evidence, or just good marketing?

What Actually Works (And What’s Mostly Social Media Hype) If you’ve spent even a few minutes online searching for “the best supplements for longevity,” you’ve likely seen the same bold promises: Reverse aging Detox your body Boost testosterone naturally Fix your hormones instantly Live to 120 with this stack HERE'S THE REALITY : most of what’s being promoted today isn’t science. It’s marketing . Many of the loudest voices in the health, wellness, and longevity space are promoting supplements they’re paid to sell, regardless of whether those products are supported by meaningful human evidence. After an extensive review of randomized controlled trials, meta-analyses, and established medical guidelines, I have compiled this guide based on REAL science  — not influencer trends or social-media hype. At Beverly Hills Institute, we do not base medical recommendations on popularity. We rely on peer-reviewed research, clinical outcomes, safety data, human physiology, and individualized patient care. Our Evidence-Based Supplement Grading System Grade A – Strongly Recommend:  Strong evidence, clear benefit, safe, high clinical value Grade B – Recommend / Reasonable:  Good evidence, modest benefit, may depend on individual factors Grade C – Consider (Situational): May help specific symptoms or populations; limited or mixed evidence Grade D – Not Recommended:  Low benefit, poor evidence, or unfavorable risk-to-value ratio Insufficient Evidence:  Trending supplements with exciting claims but inadequate high-quality human data Grade A: Strongly Recommended Supplements (Highest ROI) Psyllium Husk (Soluble Fiber) GRADE: A Why it matters: Most adults do not consume enough fiber. Psyllium has strong evidence for improving gut health and lowering LDL cholesterol, both of which are closely linked to cardiovascular risk and longevity. Typical dose: 10 g daily (for example, 5 g twice daily), always taken with a full glass of water Evidence: LDL-cholesterol reduction meta-analysis https://pubmed.ncbi.nlm.nih.gov/30239559/ Potential downsides: Temporary gas or bloating (start low and titrate) Constipation if taken without adequate water Reduced absorption of some medications (separate by ~2 hours) Creatine Monohydrate GRADE: A Why it matters: Muscle mass and strength are among the strongest predictors of longevity, independence, and fall prevention. Creatine is one of the most studied supplements in medical history and benefits both younger and older adults. Typical dose: 3–5 g daily Evidence: Updated Systematic Review & Meta-Analysis (Older Adults) https://www.mdpi.com/2072-6643/13/6/1912 ISSN Position Stand update (PDF, 2025): “safety and efficacy of creatine supplementation in exercise, sport, and medicine.”  https://www.sportsnutritionsociety.org/PDFuploads/ISSN-PDF-Upload-394.pdf Potential downsides: Mild water retention (not fat gain) GI upset if taken in large single doses Requires individualized assessment in advanced kidney disease Vitamin B12 (Only if Deficient or At Risk) GRADE: A if needed | D if not needed Who benefits most: Adults over age 50 Vegans or vegetarians Patients on metformin Patients using acid-reducing medications Typical dose: 250–500 mcg daily or 1,000 mcg two to three times weekly Evidence: NIH Vitamin B12 Fact Sheet https://ods.od.nih.gov/factsheets/VitaminB12-Consumer/ Potential downsides: Extremely safe overall Rare acne-like rash Underlying causes of deficiency should always be evaluated Grade B: Reasonable, High-Value Supplements for Many Adults Vitamin D3 GRADE: B for general adults | A if deficient or high fracture risk Why it matters: Supports bone health, muscle function, immune regulation, and healthy aging. Deficiency is very common, especially in older adults. Typical dose: 1,000–5,000 IU daily, adjusted based on blood levels Evidence: Association between vitamin D supplementation and mortality – BMJ https://www.bmj.com/content/366/bmj.l4673 Potential downsides: High doses can raise calcium levels Kidney stone risk with excessive supplementation Avoid megadosing without lab guidance Magnesium (Glycinate or Citrate) GRADE: B Why it matters: Supports sleep quality, muscle function, blood pressure regulation, and glucose metabolism. Typical dose: 200–500 mg elemental magnesium nightly Evidence: The effect of magnesium supplementation on primary insomnia in elderly. https://pubmed.ncbi.nlm.nih.gov/23853635/ Potential downsides: Diarrhea (more common with citrate or oxide) Dangerous accumulation in advanced kidney disease Interferes with thyroid medications and some antibiotics Omega-3 Fatty Acids (EPA + DHA) GRADE: B Why it matters: Supports cardiovascular health and lowers triglycerides. Typical dose: 1,000 mg daily combined EPA + DHA Evidence: Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia https://pubmed.ncbi.nlm.nih.gov/30415628/ Atrial fibrillation risk data https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.055654 Potential downsides: Increased atrial fibrillation risk in some individuals Fishy reflux Bleeding risk when combined with anticoagulants Grade C: Consider for the Right Patient CoQ10 GRADE: C for general wellness | B in heart failure Typical dose: 100–200 mg daily Evidence: Q-SYMBIO heart failure trial https://pubmed.ncbi.nlm.nih.gov/25282031/ Potential downsides: Mild GI upset May have slightly lower blood pressure Curcumin GRADE: C Typical dose: 500–1,000 mg daily of a high-absorption formulation Evidence: Osteoarthritis evidence synthesis https://pubmed.ncbi.nlm.nih.gov/34300241/ Potential downsides Heartburn Bleeding risk with anticoagulants Grade D: Popular but Low-Value Supplements Biotin for hair growth (only effective if deficient; interferes with lab tests) “Detox” cleanses (your liver and kidneys already do this) Testosterone boosters (ineffective and often stimulant-loaded) Fat burners (increase heart rate and anxiety) Apple cider vinegar gummies (minimal benefit, marketing-driven) Alkaline supplements or water (blood pH is tightly regulated) Berberine Insufficient Evidence Longevity Trends NMN / NAD+ boosters – No proven human lifespan benefit Resveratrol – Mixed data, no clinical longevity outcomes Spermidine – Early research only, no outcome-driven trials yet Important Medical Disclaimer This content is for educational purposes only and does not replace personalized medical care. Always consult a knowledgeable physician before starting any medication or supplement, especially if you take prescription medications, have heart, kidney, or liver disease, are pregnant or breastfeeding, have atrial fibrillation or arrhythmias, or use blood thinners or diabetes medications. At Beverly Hills Institute, we design supplement strategies using real labs, real data, and real medical oversight — not trends.

By Alex Foxman, MD, FACP, ABOM Founder and Medical Director, Beverly Hills Institute Most people are familiar with menopause  in women—but did you know that men experience hormone changes with age too? Often called “male menopause”  or “manopause,”  the real medical term is late-onset hypogonadism —a gradual decline in testosterone that can impact energy, mood, muscle mass, and sexual health. At the Beverly Hills Institute, we help men identify whether symptoms are simply part of aging—or a treatable hormone imbalance. What Is Male Menopause? Unlike menopause, which causes a rapid drop in estrogen, testosterone levels in men decline slowly—about 1% per year after age 40 . This change is normal, but for some, it results in measurable symptoms that affect quality of life. Not every man experiences “low T,” and not every man with lower levels needs treatment. That’s where personalized evaluation  is key. Common Symptoms of Low Testosterone Symptoms often creep up gradually and may include: Fatigue or low energy Reduced sex drive Erectile difficulties Loss of muscle mass or strength Increased body fat (especially belly fat) Mood swings, irritability, or low motivation Trouble sleeping Brain fog or reduced focus These signs can also stem from other conditions (like thyroid disorders, depression, or sleep apnea), so it’s important to evaluate the whole picture  before jumping to conclusions. What Causes Testosterone to Drop? Testosterone decline is influenced by: Aging  (natural decrease over time) Chronic conditions  (diabetes, obesity, sleep apnea) Stress and poor sleep Medications  (especially opioids and steroids) Sedentary lifestyle or poor diet Testing and Diagnosis At Beverly Hills Institute, we use a step-by-step approach: Symptom review Lab testing Rule out other causes Low testosterone is diagnosed only when both symptoms and consistently low levels are present . Do You Need Treatment? Not everyone with low testosterone needs hormone therapy.  If symptoms are mild and overall health is good, lifestyle changes may be enough. When treatment is appropriate, we consider: ✅ How severe symptoms are ✅ Your risk factors (heart health, prostate history) ✅ Your fertility goals (TRT can reduce sperm count) ✅ Lab trends and response to other interventions What Are the Treatment Options? Testosterone Replacement Therapy (TRT): FDA-approved options include injections, gels, patches, and implants Regular lab monitoring is essential (testosterone levels, PSA, red blood cell count) Lifestyle optimization can also help: Resistance training Weight loss (fat tissue lowers testosterone) Improving sleep Managing stress Treating conditions like sleep apnea At BHI, we often recommend lifestyle first , followed by targeted therapy if needed. Risks and Considerations TRT is generally safe under proper medical supervision, but possible risks include: Increased red blood cell count (which can raise clot risk) Prostate health changes (monitor PSA closely) Worsening of untreated sleep apnea Fertility suppression in younger men That’s why we offer ongoing monitoring , customized dosing, and shared decision-making. What We Offer at Beverly Hills Institute We specialize in men’s preventive and longevity health , with comprehensive care including: ✅ Hormonal evaluations (testosterone, thyroid, cortisol, DHEA) ✅ Cardiovascular screening (lipids, inflammation, calcium scoring) ✅ DEXA (full body) scans to monitor body composition ✅ Sleep and stress assessments ✅ Personalized treatment plans Our approach is evidence-based and never over-medicated . We help you make informed decisions with your long-term health in mind. Final Takeaway Male “menopause” isn’t a myth—but it’s not a crisis either. If you’re feeling off as you age, don’t ignore it. A simple blood test and personalized review can help determine whether your symptoms are hormone-related—and whether targeted changes can help you feel like yourself again. Book your evaluation today at www.bhinstitute.com Or call our office to schedule a men’s health and longevity consultation.

As the holiday season fills our days with gratitude, reflection, and time with loved ones, it also invites us to look forward with hope. And when it comes to healthcare, the future has never been brighter. 🎄✨ As we head into 2026, medicine is standing at the edge of one of the most exciting transformations in modern history—driven by artificial intelligence, smarter diagnostics, and truly personalized care. What once felt futuristic is quickly becoming part of everyday, mainstream medicine. AI Is Changing Healthcare — and It’s Finally Personal Artificial intelligence is no longer just a buzzword. In 2026, AI is becoming a trusted clinical partner, helping physicians make faster, more accurate decisions while allowing more time for what matters most: human connection. AI-driven tools are now enhancing: Early disease detection , identifying subtle patterns in labs, imaging, and vitals long before symptoms appear Personalized treatment plans , tailored to an individual’s biology, lifestyle, and goals Preventive care , shifting medicine from reactive to proactive in powerful ways Instead of replacing physicians, AI is amplifying good medicine—supporting better judgment, safer care, and better outcomes. Prevention and Longevity Take Center Stage One of the most exciting shifts heading into 2026 is the growing focus on healthspan , not just lifespan. Innovations in preventive medicine are allowing us to detect cardiovascular disease, metabolic dysfunction, bone loss, and cancer risk earlier than ever before. Expect more widespread use of: Advanced imaging and biomarker screening Continuous health monitoring at home Smarter risk prediction tools that guide lifestyle and medical decisions years ahead of disease This means fewer surprises, fewer hospitalizations, and more years lived with energy, strength, and clarity. Virtual Care Gets Smarter and More Human Virtual medicine has evolved rapidly, and in 2026 it’s no longer about convenience alone—it’s about quality. Remote care is becoming more intelligent, more data-driven, and more connected to real outcomes. Patients can expect: More meaningful virtual visits supported by real-time data Remote monitoring that actually improves care, not just collects numbers Better continuity between in-person and virtual care Healthcare is finally meeting people where they are—without sacrificing depth or personalization. Innovation With Purpose What makes this moment so exciting isn’t technology alone—it’s how thoughtfully it’s being applied. The best innovations heading into 2026 are focused on reducing friction, improving access, and restoring trust  in the physician-patient relationship. This next era of medicine is about: Earlier intervention instead of late-stage treatment Smarter use of data instead of more paperwork Empowered patients who understand their health and their options A Holiday Wish for the Year Ahead As we close out this year, we want to wish you and your family a joyful, healthy holiday season. May the coming year bring peace, resilience, and renewed focus on what matters most—your health and well-being. We are genuinely excited for what 2026 will bring. With AI-enhanced care, groundbreaking preventive tools, and a renewed emphasis on personalized medicine, the future of healthcare is not only smarter—it’s more human than ever. Here’s to a healthy, hopeful, and innovative New Year. 🎉 Happy Holidays, and welcome to the future of medicine.